FDA gives expedited approval to new groundbreaking pancreatic cancer drug

The FDA has granted expedited approval to daraxonrasib, a first-of-its-kind pill for treating the most common form of pancreatic cancer. The drug works by blocking a mutated protein that drives tumor growth in over 90% of pancreatic cancer cases, representing a breakthrough after decades of research into this deadly disease.